What is the context for the week of June 13, 2026?
The week brought insider filings, congressional disclosures, and retail sentiment data worth parsing carefully. The FOMC meets June 16-17, making this one of the more data-dense weeks of the quarter. Context matters as much as the numbers: a sale under a pre-scheduled 10b5-1 plan carries a meaningfully different signal than a discretionary open-market sale, and most of what circulated as insider selling signals this week falls into the former category.
What did the ABM Industries CEO sale actually signal?
ABM Industries CEO Scott Salmirs sold 50,000 shares on June 12 for approximately $2.32 million, executed under a Rule 10b5-1 plan established December 24, 2025. Pre-planned sales carry lower signal value than discretionary open-market sales. ABM reported record Q2 2026 revenue of $2.3 billion, up 8.4% year-over-year, with adjusted EPS of $0.90, ahead of the $0.883 consensus. The plan context and strong quarter together make this routine compensation management rather than a directional read.
The sale came in two tranches: 10,424 shares at a $46.69 weighted average and 39,576 shares at $46.25. His remaining stake sits at 395,285 shares worth roughly $18.3 million. A 10b5-1 plan locks in timing, price triggers, and volume roughly six months before execution, so executives can monetise equity without acting on material non-public information.
What did the AppLovin and ARS Pharmaceuticals insider sales show?
AppLovin ($APP) CEO Adam Foroughi sold 1,760 shares totalling $863,921, a small fraction of his 2,327,684-share position worth over $1.1 billion at current valuations. ARS Pharmaceuticals ($SPRY) CCO Eric Karas sold 25,000 shares worth approximately $250,000, reducing his stake to 12,176 shares. The APP sale is routine portfolio management; the SPRY sale is more informative if ARS has regulatory events on the near-term calendar.
Executives at companies with stocks up 300%+ over a year routinely sell small fractions. AppLovin fits that pattern. ARS is a smaller biotech where a commercial officer reducing exposure ahead of potential binary regulatory events is more informative than the ABM or APP sales.
What did the congressional disclosures show?
Four disclosures stand out: Senator Gary Peters purchased $1,001 to $15,000 of Kraft Heinz ($KHC). Rep. Mike Kelly sold $15,001 to $50,000 of Bristol-Myers Squibb ($BMY) and $1,001 to $15,000 of Comcast ($CMCSA). Rep. Suzan DelBene purchased $500,001 to $1,000,000 in Pacific Co B1 bonds. Rep. Mike Kelly also bought $15,001 to $50,000 in Southeast Energy Authority bonds. None of these show committee-alignment signals that would make them high-conviction reads.
The Kelly sales in BMY and CMCSA are directionally notable: healthcare and media sold simultaneously by a member with no obvious committee connection to either. The DelBene bond purchases are consistent with macro-defensive rotation into fixed income as FOMC uncertainty peaks. One key caveat: the STOCK Act's 30-day disclosure window means these trades could have occurred at any point in the past month. The filing date is not the trade date.
What is WallStreetBets focused on this week?
Three tickers dominate retail sentiment: SPY, SpaceX ($SPCX), and Micron ($MU). SPY discussion splits between technical analysis pointing to a potential second leg lower and FOMC positioning ahead of Wednesday's decision. SPCX momentum continues from its 19% first-day gain on June 12, with ARK Invest buying over $500 million across four ETFs on IPO day. Micron is the most substantive conversation, with AI memory demand, HBM capacity sold out, and Q3 fiscal 2026 earnings on June 24 with street revenue estimates near $8.9 billion.
What are the options flow and sector signals showing?
AI semiconductor names (INTC, SNDK, LRCX) show call-side dominance with layered hedges in MU and TSM. Healthcare and consumer staples (MRK, IMVT, KO) attract call premium. Consumer cyclicals (AMZN, BABA, PDD) carry long-dated puts. Energy (EXE, PBR, YPF) shows elevated put demand after oil's 8.5% weekly decline on Iran deal signals. The pattern across sectors points to positioning for FOMC uncertainty rather than a directional view on any single sector.
The semiconductor setup is bullish but hedged: call-side dominance with protective positions in MU and TSM tells you the market wants sector upside but isn't running unhedged into both Micron earnings and Wednesday's dot plot. Healthcare and staples buying upside without full delta exposure shows institutions rotating defensively without fully reducing equity risk.
What should traders watch this week?
The FOMC meets June 16-17 with the rate decision and dot plot at 2:00 PM ET on June 17, followed by Warsh's press conference at 2:30 PM ET. This is his first quarterly Summary of Economic Projections as Fed chair. A hawkish dot shift reprices the long end and compresses growth multiples. A neutral dot plot with ambiguous language gives the market room to recover from last week's volatility.
June OPEX lands June 18, the day after the FOMC. Micron reports June 24. The insider and congressional data tells you where individual actors positioned. Wednesday tells you whether they were right.
Track live insider transactions, congressional filings, and options flow at opticalpha.net/terminal. 14-day free trial, no credit card required.